Spots Global Cancer Trial Database for Phase I Study of RiMO-401 With Radiation in Advanced Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Study of RiMO-401 With Radiation in Advanced Tumors
Official Title: Phase I Dose-Escalation Study of RiMO-401 With Radiation in Advanced Tumors
Study ID: NCT06182579
Interventions
Study Description
Brief Summary: This is a single arm study of RiMO-401 with radiation in patients with advanced tumors. A single escalation dose of RiMO-401 is intratumorally injected in a 3+3 study design to identify the recommended dose.
Detailed Description: Primary Objectives: ⢠To determine the tolerability of RiMO-401 with palliative radiation as assessed by CTCAEv5 Secondary Objectives: * To determine clinical response of RiMO-401 with palliative radiotherapy * To characterize adverse events of RiMO-401 in patients with advanced cancers * To characterize the pharmacokinetics of RiMO-401 with palliative radiation The target population comprises patients with clinically accessible lesions that can be trated with palliative radiation.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Illinois at Chicago, Chicago, Illinois, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
